The Medicine Maker / Issues / 2017 / Articles / Apr / The Power List 2017
Discovery & Development Biosimilars Business Practice Clinical Trials Contract Development Services Quality & Compliance Standards & Regulation Small Molecules Advanced Medicine Technology and Equipment Vaccines Analytical Science Trends & Forecasts Contract Manufacturing Services Development & Clinical Outsourcing Regulation & Standards Small Molecules Cell & Gene Facilities & Equipment Technology & Manufacturing

The Power List 2017

04/21/2017 1 min read

Share

With two somewhat provocative Power Lists behind us, we once again forge ahead with our mission to celebrate the fantastic individuals involved in bettering the pharma industry, and in bringing life-changing medicines to market. Welcome to the 2017 Power List, where we delve into the passions, pivotal moments and predictions of the Top 100 most influential people in the drug development industry divided into four categories – each made up of 25 names and led with a Top 10: Masters of the Bench, Industry Influencers, Business Captains, and Champions of Change.

The Power List 2017

Recommended

Related Content

The Monoclonal Milestone
Biosimilars
The Monoclonal Milestone

December 1, 2014

0 min read

The launch of the world’s first biosimilar monoclonal antibody was a big step forward from a regulatory and scientific standpoint. Will there be enough room at the table?

Safety First - Sizing Up Biologics Side Effects
Standards & Regulation Biosimilars
Safety First - Sizing Up Biologics Side Effects

December 2, 2014

0 min read

Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated – especially when products share the same name.

Singular Head of Generics
Biosimilars
Singular Head of Generics

November 6, 2014

0 min read

Sitting Down With… Nick Haggar, Head of Western Europe, Middle East & Africa, Sandoz, and President of the European Generic Medicines Association (EGA).

Celebrating the Potential of Biosimilars
Supply Chain Biosimilars Bioprocessing - Upstream & Downstream
Celebrating the Potential of Biosimilars

February 5, 2025

3 min read

A look at how biosimilars can increase patient access to essential medicines, as well as improve performance in national and international healthcare systems.